UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: October 2020 (Report No. 2)

 

Commission file number: 001-37600

 

NANO DIMENSION LTD.

(Translation of registrant’s name into English)

 

2 Ilan Ramon

Ness Ziona 7403635 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒          Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____

 

 

 

 

 

 

CONTENTS

 

This Report of Foreign Private Issuer on Form 6-K consists of the Registrant’s (i) Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2020, which is attached hereto as Exhibit 99.1; and (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations for the six months ended June 30, 2020, which is attached hereto as Exhibit 99.2.

 

This Report on Form 6-K (including exhibits thereto) is incorporated by reference into the registration statements on Form F-3 (File No. 333-217173, 333-233905, 333-237668 and 333-249184) and Form S-8 (File No. 333-214520 and 333-248419) of the Company, filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Exhibit  No.    
     
99.1   Nano Dimension Ltd.’s Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2020.
     
99.2   Nano Dimension Ltd.’s Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Six Months Ended June 30, 2020.

  

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Nano Dimension Ltd.
  (Registrant)
     
Date: October 19, 2020 By: /s/ Yael Sandler
  Name:  Yael Sandler
  Title: Chief Financial Officer

 

 

2

 

Exhibit 99.1

 

Nano-Dimension Ltd.

 

Unaudited Condensed Consolidated Interim Financial Statements as of June 30, 2020

 

Table of Contents

 

  Page
Unaudited Condensed Consolidated Interim Financial Statements:  
   
Unaudited Condensed Consolidated Interim Statements of Financial Position F-2
   
Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income F-3
   
Unaudited Condensed Consolidated Interim Statements of Changes in Equity F-4
   
Unaudited Condensed Consolidated Interim Statements of Cash Flow F-5
   
Notes to the Unaudited Condensed Consolidated Interim Financial Statements F-6 - F-12

 

F-1

 

 

Nano Dimension Ltd.

Unaudited Condensed Consolidated Interim Statements of Financial Position as at

(In thousands of USD)

 

    June 30,     December 31,  
    2019     2020     2019(*)  
                   
Assets                  
Cash and cash equivalents     5,290       39,665       3,894  
Bank deposits     -       9,800       -  
Restricted deposits     31       60       31  
Trade receivables     1,174       541       1,816  
Other receivables     573       503       570  
Inventory     3,967       3,956       3,543  
Total current assets     11,035       54,525       9,854  
                         
Restricted deposits     351       376       377  
Property plant and equipment, net     5,350       4,391       4,743  
Right of use asset     1,640       2,258       2,673  
Intangible assets     5,597       4,826       5,211  
Total non-current assets     12,938       11,851       13,004  
Total assets     23,973       66,376       22,858  
                         
Liabilities                        
Trade payables     819       669       850  
Other payables     3,153       3,678       3,575  
Total current liabilities     3,972       4,347       4,425  
                         
Liability in respect of government grants     867       892       1,044  
Lease liability     1,273       1,699       2,089  
Liability in respect of warrants, rights to purchase and convertible notes     2,804       1,834       3,698  
Total non-current liabilities     4,944       4,425       6,831  
Total liabilities     8,916       8,772       11,256  
                         
Equity                        
Share capital     5,559       66,236       6,441  
Share premium and capital reserves     63,850       61,748       65,202  
Treasury shares     (1,509 )     (1,509 )     (1,509 )
Presentation currency translation reserve     1,431       1,431       1,431  
Accumulated loss     (54,274 )     (70,302 )     (59,963 )
Total equity     15,057       57,604       11,602  
Total liabilities and equity     23,973       66,376       22,858  

 

(*) The December 31, 2019 balances were derived from the Company’s audited annual financial statements.

 

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

 

F-2

 

 

Nano Dimension Ltd.

Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income

(In thousands of USD, except per share amounts)

 

    For the Six-Month 
Period Ended
June 30,
 
    2019     2020  
             
Revenues     2,850       990  
                 
Cost of revenues     1,959       589  
                 
Cost of revenues - amortization of intangible     386       386  
                 
Total cost of revenues     2,345       975  
                 
Gross profit     505       15  
                 
Research and development expenses, net     4,474       3,597  
                 
Sales and marketing expenses     2,871       1,749  
                 
General and administrative expenses     1,590       1,943  
                 
Operating loss     (8,430 )     (7,274 )
                 
Finance income     7,317       130  
                 
Finance expense     1,551       3,195  
                 
Total comprehensive loss     (2,664 )     (10,339 )
                 
Basic and diluted loss per share (USD)  (after 1:50 reverse split effective June 29, 2020- see note 7)     (0.82 )     (0.55 )

 

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

 

F-3

 

 

Nano Dimension Ltd.

Unaudited Condensed Consolidated Interim Statements of Changes in Equity

(In thousands of USD) 

 

    Share
capital
    Share
premium
and
capital
reserves
    Treasury
shares
    Presentation
currency
translation
reserve
    Accumulated
loss
    Total
equity
 
                                     
For the six months ended June 30, 2020:                                    
Balance as of January 1, 2020     6,441       65,202       (1,509 )     1,431       (59,963 )     11,602  
Issuance of ordinary shares, net     55,512       (9,743 )     --       --       --       45,769  
Conversion of convertible notes     2,013       (78 )     --       --       --       1,935  
Exercise of warrants and options     2,270       2,883       --       --       --       5,153  
Share-based payments     --       3,484       --       --       --       3,484  
Net loss     --       --       --       --       (10,339 )     (10,339 )
                                                 
Balance as of June 30, 2020     66,236       61,748       (1,509 )     1,431       (70,302 )     57,604  
                                                 
For the six months ended June 30, 2019:                                                
                                                 
Balance as of January 1, 2019     3,291       63,969       (1,509 )     1,431       (51,610 )     15,572  
                                                 
Issuance of ordinary shares, net     2,216       (632 )     --       --       --       1,584  
Exercise of rights to purchase     52       311       --       --       --       363  
Share-based payments     --       202       --       --       --       202  
Net loss     --       --       --       --       (2,664 )     (2,664 )
                                                 
Balance as of June 30, 2019     5,559       63,850       (1,509 )     1,431       (54,274 )     15,057  

 

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

 

F-4

 

 

Nano Dimension Ltd.

Unaudited Condensed Consolidated Interim Statements of Cash Flow

(In thousands of USD) 

 

    For the six months ended
June 30,
 
    2019     2020  
Cash flow from operating activities            
Net loss   (2,664 ) (10,339 )
                 
Adjustments:                
                 
Depreciation and amortization     1,336       1,291  
Changes in liability in respect of government grants     (2 )     (2 )
Revaluation of financial liabilities accounted at fair value     (7,316 )     3,023  
Issuance expenses recognized as finance expense     1,224       -  
Financing expenses (income)     268       (17 )
Loss from disposal and sale of fixed assets     17       -  
Share-based payments     193       945  
      (4,280 )     5,240  
Changes in assets and liabilities:                
Increase in inventory     (1,223 )     (410 )
Decrease (increase) in other receivables     (3 )     67  
Decrease in trade receivables     139       1,275  
Increase in other payables     333       113  
Decrease in trade payables     (599 )     (172 )
      (1,353 )     873  
Net cash used in operating activities     (8,297 )     (4,226 )
                 
Cash flow from investing activities                
Increase in bank deposits     -     (9,800 )
Increase in restricted deposits     (14 )     (28 )
Acquisition of property plant and equipment     (316 )     (152 )
Proceeds from sale of fixed assets     -       2  
Net cash used in investing activities     (330 )     (9,978 )
                 
Cash flow from financing activities                
Proceeds from issuance of ordinary shares, warrants and rights to purchase, net     10,561       48,307  
Lease payments     (534 )     (528 )
Proceeds from exercise of warrants and rights to purchase     282       2,200  
Amounts recognized in respect of government grants liability, net     (96 )     (107 )
Net cash provided by financing activities     10,213       49,872  
                 
Increase in cash and cash equivalents     1,586       35,668  
Cash and cash equivalents at beginning of the period     3,753       3,894  
Effect of exchange rate fluctuations on cash     (49 )     103  
Cash and cash equivalents at end of period     5,290       39,665  
                 
Non-cash transactions:                
Property plant and equipment acquired on credit     3       5  
Conversion of warrants to equity not for cash     81       2,953  

 

The accompanying notes are an integral part of these unaudited condensed consolidated interim financial statements.

 

F-5

 

 

Nano Dimension Ltd.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

 

Note 1 - General

 

a.

Reporting entity

 

Nano Dimension Ltd. (the “Company”) is an Israeli resident company incorporated in Israel. The address of the Company’s registered office is 2 Ilan Ramon St., Ness Ziona, Israel. The unaudited condensed consolidated interim financial statements of the Company as of June 30, 2020 comprise the Company and its subsidiaries in Israel, in the United States and in Hong Kong (together referred to as the “Group”). The Company engages, by means of the subsidiary Nano Dimension Technologies Ltd. (“Nano–Technologies”), in the development and commercialization of a three-dimensional (3D) printer and nanotechnology based conductive and dielectric inks, which are supplementary products to the 3D printer. Since March 2016, American Depositary Shares (“ADSs”) representing the Company’s ordinary shares have been trading on the Nasdaq Capital Market.

 

b. Since August 25, 2014, the Company has devoted substantially all of its financial resources to develop its products and has financed its operations primarily through the issuance of equity securities. The amount of the Company’s future net profits or losses will depend, in part, on the rate of its future expenditures, its ability to generate significant revenues from the sale of its products, and its ability to obtain funding through the issuance of securities, strategic collaborations or grants. Starting in the fourth quarter of 2017, the Group began to commercialize its products and has generated revenues, mainly from sales of its 3D printers. The Group’s ability to generate revenue and achieve profitability depends on its ability to successfully commercialize its products.

 

Note 2 - Basis of Presentation

 

a.

Statement of Compliance

 

These unaudited condensed consolidated interim financial statements have been prepared in accordance with International Accounting Standard (“IAS”) 34 Interim Financial Reporting and do not include all of the information required for full annual financial statements. They should be read in conjunction with the financial statements as of and for the year ended December 31, 2019 (the “Annual Financial Statements”).

 

These condensed consolidated interim financial statements as at and for the six months ended June 30, 2020 were authorized for issuance by the Company’s Board of Directors on October 19, 2020.

 

F-6

 

 

Nano Dimension Ltd.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

 

Note 2 - Basis of Presentation (Cont’d)

 

b.

Use of Estimates and Judgments

 

The preparation of financial statements in conformity with International Financial Reporting Standards requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

 

The significant judgments made by management in applying the Group’s accounting policies and the principal assumptions used in the estimation of uncertainty were the same as those that applied to the Annual Financial Statements.

 

Note 3 – Material Events During the Reporting Period

 

a. Effective January 2, 2020, Mr. Yoav Stern was appointed as President and Chief Executive Officer (“CEO”) of the Company. He succeeded the co-founder and former CEO, Amit Dror, who took the executive role of Customer Success Officer reporting directly to Mr. Stern.

  

b. In February 2020, the Company issued, pursuant to a public offering in the United States, an aggregate of 2,333,000 ADSs and 116,650 non-tradable warrants to the underwriters (exercisable into 116,650 ADSs). Also, in February 2020, the underwriters partly exercised their over-allotment option to purchase an additional 255,318 ADSs and 12,766 non-tradable warrants to the underwriters (exercisable into 12,766 ADSs), bringing the total gross proceeds from the offering to approximately $3,882,000, before deducting underwriting discounts and commissions and other offering-related expenses.

 

c. Pursuant to a securities purchase agreement dated August 30, 2019, in September 2019, the Company issued convertible notes, with an aggregate principal amount of approximately $4.3 million and undertook to issue an additional approximately $2.7 million of notes to be received in two subsequent closings. See note 11.B.4 to the Annual Financial Statements. During 2019, approximately $1.8 million of convertible notes were converted into ADSs.  During 2020 and prior to February 4, 2020, an aggregate of approximately $0.2 million of convertible notes were converted into ADSs. On February 4, 2020, the Company decreased the conversion price of approximately 85% of the convertible notes to $1.74 per ADS, and in consideration of the reduced conversion price, the holders of such convertible notes agreed to convert such convertible notes into ADSs concurrently with the closing of the offering mentioned in Note 3.b above. Additionally, the Company agreed to amend the exercise price under the warrants issued to such investors to $1.914 per ADS, and the Company and the investors agreed to terminate substantially all remaining obligations, including the two subsequent closings.

 

d. In April 2020, the Company issued, pursuant to a public offering in the United States, an aggregate of 17,428,000 ADSs, 430,000 pre-funded warrants (exercisable into 430,000 ADSs) and 892,900 non-tradable warrants to the underwriters (exercisable into 892,900 ADSs). Also, in April 2020, the underwriters partly exercised their over-allotment option to purchase an additional 1,204,114 ADSs and 60,206 non-tradable warrants to the underwriters (exercisable into 60,206 ADSs), bringing the total gross proceeds from the offering to approximately $13,343,000, before deducting underwriting discounts and commissions and other offering-related expenses. In May 2020, the pre-funded warrants were exercised.

 

e. In May 2020, the Company issued, pursuant to a public offering in the United States, an aggregate of 17,950,000 ADSs and 897,500 non-tradable warrants to the underwriters (exercisable into 897,500 ADSs). The total gross proceeds from the offering were approximately $35,900,000, before deducting underwriting discounts and commissions and other offering-related expenses.

 

f.

Following the outbreak of the coronavirus (COVID-19) in China in December 2019, and it reaching many other countries as well at the beginning of 2020, there was a decrease in economic activity in many areas around the world, including Israel, the U.S., Europe and Asia-Pacific. The spread of the virus has led, inter alia, to a decrease in global transportation, restrictions on travel and work that were announced by the State of Israel and other countries around the world. As a result of the COVID-19 pandemic’s global effects, many entities held-off on capital expenses; thus, the Company witnessed a significant decrease in the Group's revenues from the first quarter of 2020.

 

Since this event is not under the control of the Group, the Group is continuing to regularly follow the changes on the markets in Israel and the world and is examining the mid- and long- term effects on the business results of the Group.

 

F-7

 

 

Nano Dimension Ltd.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

 

Note 4 - Share-Based Payments

 

a. In March 2020, the Company issued options to purchase 294,828 ADSs to Yoav Stern, the Company’s CEO, with an exercise price of $1.09 per ADS. 99.9% of the options vest at the grant date, and the remaining options will vest 3 years after the grant date. See also note 9.b regarding forfeiting of those options after the reporting date.

 

b. In May and June 2020, the Company issued options to purchase 3,247,000 ADSs to employees, consultants and officers of the Company at an exercise price of $0.70 per ADS. In addition, the Company issued 778,000 restricted share units to employees of the Company. The share options and restricted share units vest over a period of three years.

 

c. The fair value of the aforesaid share options was estimated on the grant date using the Black-Scholes-Merton option pricing model. The following is the data used in determining the fair value of the share options:

 

  Options- CEO     Options- Employees, Officers, Consultants     RSUs- Employees  
Grant Month   March      May, June      May, June  
Number of share options granted (ADSs)     294,828       3,247,000       778,000  
Fair value at the grant date (thousands of USD)     182       4,254       2,065  
Range of share price (USD)     1.09       0.839 – 2.67       2.12 – 2.67  
Range of exercise price (USD)     1.09       0.70       0  
Range of expected share price volatility     63.43 %     67.77%-80.57 %     NA  
Range of estimated life (years)     7       4.00-7.00       NA  
Range of weighted average of risk-free interest rate     0.36 %     0.362%-0.625 %     NA  
Expected dividend yield     --       --       --  

  

  Expenses in the amount of $945,000 were recognized as a salary expense in the six month period ended June 30, 2020 ($193,000 in the six month period ended June 30, 2019).

 

d. Regarding additional share-based payment transactions after the reporting date, see Note 9.

 

F-8

 

 

Nano Dimension Ltd.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

 

Note 5 - Financial Instruments

 

(1) Financial instruments measured at fair value for disclosure purposes only

 

The carrying amounts of certain financial assets and liabilities, including cash, trade receivables, other receivables, deposits, trade and other payables are the same as or approximate to their fair value.

 

(2) Fair value hierarchy of financial instruments measured at fair value

 

The table below presents an analysis of financial instruments measured at fair value on a temporal basis, using valuation methodology in accordance with the fair value hierarchy level as defined below.

 

When determining the fair value of an asset or liability, the Company uses observable market data as much as possible. There are three levels of fair value measurements in the fair value hierarchy that are based on the data used in the measurement, as follows:

 

Level 1: quoted prices (unadjusted) in active markets for identical instruments
Level 2: inputs other than quoted prices included within Level 1 that are observable, either directly or indirectly
Level 3: inputs that are not based on observable market data (unobservable inputs)

 

In February 2020, as a result of changes to the terms of the warrants issued pursuant to a securities purchase agreement dated August 30, 2019 (see note 3.c), the fair value measurement of those warrants has changed from level 3 to level 2.

 

As of June 30, 2020, the Company had a long term financial liability in respect to warrants in the amount of $1,834,000, measured in level 2.

 

Details regarding fair value measurement at Level 2

 

The fair value of the warrants was measured using the Black-Scholes model. The following inputs were used to determine the fair value:

 

Expected term of warrant (1) – 3.6 to 4.18 years.

Expected volatility (2) – 103.1% to 110%.

Risk-free rate (3) – 0.25% to 0.3%.

Expected dividend yield – 0%.

 

(1) Based on contractual terms.
(2) Based on the historical volatility of the Company’s ordinary shares and ADSs.
(3) Based on traded zero-coupon U.S. treasury bonds with maturity equal to expected terms.

 

F-9

 

 

Nano Dimension Ltd.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

 

Note 6 – Revenues

 

The table below provides information regarding receivables, contract assets and contract liabilities deriving from contracts with customers.

 

    June 30,  
    2019     2020  
    Thousands USD     Thousands USD  
Trade receivables     1,174       515  
Contract assets     -       26  
Contract liabilities     766       917  

 

The contract liabilities primarily relate to the advance consideration received from customers for contracts containing yearly warranty services. The revenue is recognized on a straight line basis over the contract period.

 

In the following tables, the Group’s revenue is disaggregated by major products, primary geographical market and timing of revenue recognition.

 

Revenues per major products:

 

    For the six-month Ended
June 30
 
    2019     2020  
    Thousands USD     Thousands USD  
             
Consumables     222       265  
Printing services     -       52  
Sales of printers     2,577       673  
Total     2,799       990  
Printers rental     51       -  
Total revenues     2,850       990  

 

F-10

 

 

Nano Dimension Ltd.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

 

Note 6 – Revenues (Cont’d)

 

Revenues per geographical locations:

 

    For the six-month Ended
June 30
 
    2019     2020  
    Thousands USD     Thousands USD  
U.S.     1,040       582  
Asia Pacific     639       117  
Europe and Israel     1,171       291  
Total revenues     2,850       990  

 

Revenues per timing of revenue recognition:

 

    For the six-month Ended
June 30
 
    2019     2020  
    Thousands USD     Thousands USD  
Goods and services transferred over time     327       273  
Goods transferred at a point in time     2,523       717  
Total revenues     2,850       990  

 

Note 7 – Capital and Reserves

 

Share capital and share premium

 

During the period the Group recognized the following amounts within share capital and share premium:

 

    For the six months ended  
    June 30,
2020
 
    Thousands USD  
Issued for cash, net of issuance expenses     45,769  
Conversion of convertible notes into ordinary shares during the period     1,935  
Exercise of warrants and options into ordinary shares during the period     5,153  
Total     52,857  

 

Issuance expenses of $7,357,000 are presented as a deduction from equity.

 

Following the approval of its shareholders on April 16, 2020, the Board of Directors of the Company approved a 1-for-50 reverse split of the Company’s share capital. The implementation of the reverse split resulted in a reduction in the issued and outstanding ordinary shares, and the increase of the par value per ordinary share from NIS 0.10 to NIS 5.00 per ordinary share. Concurrently with the reverse split, the Company effected a corresponding change in the ratio of ordinary shares to each of the Company’s ADSs, such that its ratio of ADSs to ordinary shares has changed from one (1) ADS representing fifty (50) ordinary shares to a new ratio of one (1) ADS representing one (1) ordinary share. The effective date of this reverse split was June 29, 2020. All options and warrants of the Company outstanding immediately prior to the reverse split were appropriately adjusted by dividing the number of ordinary shares into which the options and warrants are exercisable by 50 and multiplying the exercise price thereof by 50, as a result of the reverse split. All the figures in these financial statements relating to share capital were appropriately adjusted to reflect the above mentioned reverse split.

 

Convertible notes

 

In January, February and March 2020, approximately $2.5 million of convertible notes were converted into 1,394,922 ordinary shares of NIS 5.00 par value per share. For more information on the conversion of convertible notes during the reporting period, see note 3.c.

 

F-11

 

 

Nano Dimension Ltd.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

 

Note 8 - Related and Interested Parties

 

A. Transactions with key management personnel

 

Benefits to key management personnel

 

Key management personnel received benefits in the amount of $1,332,000 during the six month period ended June 30, 2020 (in the six month period ended June 30, 2019: $567,000) in the form of short-term employee benefits and share-based payments.

 

B. Other transactions with related and interested parties

 

For transactions with related parties after the reporting date, see note 9 below.

 

Note 9 - Events after the Reporting Date

 

a. On July 7, 2020, following approval of the general meeting of the Company’s shareholders, the Company granted options to purchase 1,440,000 ADSs to officers and directors of the Company at an exercise price of $0.70 per ADS.

 

b. Following approval of the general meeting of the Company’s shareholders from July 7, 2020, the Company issued 6,880,402 warrants to purchase 6,880,402 ADSs to the Company’s CEO and President, Mr. Yoav Stern, for consideration of $150,000. The warrants have an exercise price of $0.75 per ADS, will vest over a period of two and a half years and will expire after 7 years. Simultaneously with the issuance of the warrants, Mr. Stern forfeited options to purchase 581,000 ADSs, previously granted to him. In addition, as long as Mr. Stern is employed by the Company or is a member of the Company’s board of directors, Mr. Stern may invest an additional amount up to $50,000 to buy Series B Warrants, in an amount equal to 10% of the Company’s fully diluted capital. The exercise price per ADS under the Series B Warrants will be the average of the daily volume weighted average price of the ADSs for the 10 consecutive trading days ending on the trading day that is immediately prior to the date of the applicable notice to purchase the Series B Warrants. The Company is examining the accounting treatment for the above mentioned warrants, and it currently estimates that the grant of the warrants will be treated as a modification of the terms of equity instruments under International Financial Reporting Standard No. 2. Based on a preliminary estimation, the fair value of the grant that will be recorded as share-based compensation expenses is expected to be in the range of $15 million to $20 million and is subject to further accounting examination. In the same general meeting, the Company’s shareholders approved the terms of compensation of the Company’s CEO and President.

 

c. On August 12, 2020, the Company issued options to purchase 93,000 ADSs to employees of the Company at an exercise price of $0.70 per ADS. In addition, the Company issued 481,000 restricted share units to employees of the Company.

 

d. On September 6, 2020, the Company issued 1,500,000 warrants to purchase 1,500,000 ADSs to the Company’s director, Mr. Yaron Eitan, in consideration of $150,000. The warrants have an exercise price of $2.25 per ADS, will vest over a period of three years and will expire after 7 years.

 

e. On September 29, 2020, the Company issued options to purchase 1,000,000 ADSs to employees and officers of the Company at an exercise price of $1.58 per ADS. In addition, the Company issued 100,000 restricted share units to employees of the Company.

 

f. In October 2020, the Company issued, pursuant to a public offering in the United States, an aggregate of 7,356,521 ADSs and 367,826 non-tradable warrants to the underwriters (exercisable into 367,826 ADSs). The total gross proceeds from the offering were approximately $16,900,000, before deducting underwriting discounts and commissions and other offering-related expenses.

 

 

F-12

 

 

 

Exhibit 99.2

  

MANAGEMENT’S DISCUSSION AND ANALYSIS OF

FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

For the Six Months Ended June 30, 2020

 

Cautionary Statement Regarding Forward-Looking Statements

 

Certain information included herein may be deemed to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Forward-looking statements are often characterized by the use of forward-looking terminology such as “may,” “will,” “expect,” “anticipate,” “estimate,” “continue,” “believe,” “should,” “intend,” “project” or other similar words, but are not the only way these statements are identified. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, expansion of marketing and channel activities, converting prospects to customers, statements that contain projections of expected market size, results of operations or of financial condition, expected capital needs and expenses, statements relating to the research, development, completion and use of our products, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

 

Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among other things:

 

  the overall global economic environment;
     
  the impact of competition and new technologies;
     
  general market, political and economic conditions in the countries in which we operate;
     
  projected capital expenditures and liquidity;
     
  changes in our strategy;
     
  the impact of the COVID-19 pandemic on our business and operating results; and
     
  litigation.

 

The foregoing list is intended to identify only certain of the principal factors that could cause actual results to differ. For a more detailed description of the risks and uncertainties affecting our company, reference is made to our Annual Report on Form 20-F for the year ended December 31, 2019, or our Annual Report, which is on file with the Securities and Exchangel Commission, or the SEC, and the other risk factors discussed from time to time by our company in reports filed or furnished to the SEC.

 

Except as otherwise required by law, we undertake no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

 

 

 

 

General

 

Introduction

 

Unless indicated otherwise by the context, all references in this report to “Nano Dimension”, the “Company”, “we”, “us” or “our” are to Nano Dimension Ltd. and its subsidiaries. When the following terms and abbreviations appear in the text of this report, they have the meanings indicated below:

 

  dollars” or “$” means United States dollars; and
     
  NIS means New Israeli Shekels.

 

You should read the following discussion and analysis in conjunction with our unaudited consolidated financial statements for the six months ended June 30, 2020 and notes thereto, and together with our audited consolidated financial statements for the year ended December 31, 2019 and notes thereto filed with the SEC as part of our Annual Report.

 

Overview

 

We are a leading additive electronics provider. We believe our flagship proprietary DragonFly system is the first and only precision system that produces professional multilayer circuit-boards (PCB), RF antennas, sensors, conductive geometries, and molded connected devices for rapid prototyping through custom additive manufacturing. We have been actively developing our additive manufacturing technology since 2014, and since that time we have listed our securities on the Tel Aviv Stock Exchange and Nasdaq, and have spent approximately $80 million to build our additive electronics company. With our unique additive manufacturing technology for 3D printed electronics, we are targeting the growing market for smart electronic devices that rely on printed circuit boards, connected devices, RF components and antennas, sensors, and smart products, including IoT.

 

We began commercializing our first professional grade DragonFly 3D printer during the fourth quarter of 2017. The first of its kind 3D printer uses our proprietary inks and integrated software to quickly create functional electronics such as multilayered printed circuit boards (PCBs), sensors, conductive geometries, antennas, molded connected devices and other devices for rapid prototyping and custom additive manufacturing of smart products.

 

Financial Highlights

 

  Total revenues for the six months ended June 30, 2020 were $990,000, compared to $2,850,000 in the six months ended June 30, 2019. The decrease is attributed to less sales of DragonFly systems in the first half of 2020, which the Company primarily attributes to the impact of Covid-19, which caused many entities to hold-off on capital expenditures.
     
  Net loss for the six months ended June 30, 2020 was $10,339,000, or $0.55 per share, compared to $2,664,000, or $0.82 per share, in the six months ended June 30, 2019. The increase is mainly attributed to finance expenses of approximately $3,023,000 that were recognized in the first half of 2020 as a result of the change in the fair value of warrants and convertible notes, compared to finance income of approximately $7,316,000 in the first half of 2019 as a result of the change in the fair value of warrants and rights to purchase ADSs. The decrease in the loss per share is attributed to an increase in issued share capital as a result of the offerings during the first half of 2020.
     
  Cash and cash equivalents, together with short-term bank deposits totaled $49,525,000 as of June 30, 2020, compared to $3,925,000 as of December 31, 2019. The increase compared to December 31, 2019, mainly reflects proceeds received from the sale of ADSs representing the Company’s ordinary shares in the first half of 2020, less cash used in operations during the six months ended June 30, 2020.
     
  Shareholders’ equity totaled $57,604,000 as of June 30, 2020, compared to $11,602,000 as of December 31, 2019.

 

Critical Accounting Policies

 

The preparation of financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. A comprehensive discussion of our critical accounting policies is included in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” section in our Annual Report.

 

2

 

 

Results of Operations

 

The following discussion of our unaudited results of operations for the six month periods ended June 30, 2020 and 2019, included in the following table, which presents selected financial information data, is based upon our unaudited statements of operations contained in our financial statements for those periods, and the related notes.

 

    For the Six-Month 
Period Ended
June 30,
 
    Thousands USD  
    2019     2020  
             
Revenues     2,850       990  
                 
Cost of revenues     1,959       589  
                 
Cost of revenues - amortization of intangible     386       386  
                 
Total cost of revenues     2,345       975  
                 
Gross profit     505       15  
                 
Research and development expenses, net     4,474       3,597  
                 
Sales and marketing expenses     2,871       1,749  
                 
General and administrative expenses     1,590       1,943  
                 
Operating loss     (8,430 )     (7,274 )
                 
Finance income     7,317       130  
                 
Finance expense     1,551       3,195  
                 
Total comprehensive loss     (2,664 )     (10,339 )
                 
Basic and diluted loss per share (USD)  (after 1:50 reverse split effective June 29, 2020)     (0.82 )     (0.55 )

  

Six Months Ended June 30, 2020 Compared with Six Months Ended June 30, 2019

 

Revenues. Our revenues are derived primarily from sales of printers to customers, warranty and service contracts, and sale of ink and other consumables to those customers. Total revenues for the six months ended June 30, 2020 were $990,000, compared to $2,850,000 in the six months ended June 30, 2019. The decrease is attributed to less sales of DragonFly systems in the first half of 2020, which the Company primarily attributes to the impact of Covid-19, which caused many entities to hold-off on capital expenditures.

 

Cost of Revenues. Cost of revenues consists mainly of cost of printers sold, cost of maintenance, and ink and other consumables costs, as well as amortization of intangible assets. Our cost of revenues for the six months ended June 30, 2020, were $975,000, compared to $2,345,000 in the six months ended June 30, 2019. Cost of revenues for the six months ended June 30, 2020, consists of $234,000 in respect of cost of printers and LDM system upgrades sold, $255,000 in respect of warranty cost, $84,000 for ink and other consumables, $16,000 in respect of printing services, and an additional $386,000 in respect of amortization of intangible assets. The decrease for the six months ended June 30, 2020 resulted primarily from the above-mentioned decrease in revenues.

 

3

 

 

Research and Development. Research and Development, or R&D, expenses consist primarily of salaries of employees engaged in on-going R&D activities, materials, depreciation, rent, and other related costs. R&D expenses for the six months ended June 30, 2020 were $3,597,000, compared to $4,474,000 in the six months ended June 30, 2019. The decrease resulted primarily from a decrease in payroll and related expenses as a result of the Company’s decision to allocate less resources to R&D, as well as a decrease in materials expenses.

  

Sales and marketing. Sales and marketing expenses consist primarily of salaries of sales and marketing employees, marketing and advertising expenses, travel and related expenses, and other sales and marketing costs. Sales and marketing expenses for the six months ended June 30, 2020, were $1,749,000, compared to $2,871,000 in the six months ended June 30, 2019. The decrease is mainly attributed to a decrease in payroll and related expenses and marketing and advertising expenses, as a result of fewer sales and marketing employees.

 

General and administrative. General and administrative, or G&A, expenses consist primarily of professional services expenses, salaries and share based payments expenses for general and administrative employees, and other administrative costs. G&A expenses for the six months ended June 30, 2020 were $1,943,000, compared to $1,590,000 in the six months ended June 30, 2019. The increase is mainly attributed to an increase in share-based payments expenses.

 

Operating Loss. Based on the foregoing, we recorded an operating loss of $7,274,000 for the six months ended June 30, 2020, compared to $8,430,000 in the six months ended June 30, 2019. 

 

Finance income and expenses. Finance income and expenses consist of finance expense or income as a result of the change in the fair value of warrants and convertible notes that were issued in our 2019 offerings, bank fees, revaluation of liability in respect of government grants and lease liability, and exchange rate differences. Finance expenses, net, for the six months ended June 30, 2020, were $3,065,000, compared to finance income, net, of $5,766,000 in the six months ended June 30, 2019. The increase in expenses resulted primarily from finance expenses as a result of the change in the fair value of warrants and convertible notes, mainly due to changes in the share price.

 

Net Loss. Net loss for the six months ended June 30, 2020, was $10,339,000, or $0.55 per share, compared to $2,664,000, or $0.82 per share, in the six months ended June 30, 2019.

 

Liquidity and Capital Resources

 

From August 2014 through June 30, 2020, we have funded our operations principally with $117,319,000 from the issuance of ordinary shares (including ADSs), warrants and convertible notes. As of June 30, 2020, we had $39,665,000 in cash and cash equivalents and $9,860,000 in short-term bank deposits.

 

The table below presents our cash flows:

 

    Six Month Periods Ended
June 30,
 
(in thousands of U.S. dollars)   2019     2020  
Operating activities     (8,297 )     (4,226 )
                 
Investing activities     (330 )     (9,978 )
                 
Financing activities     10,213       49,872  
                 
Net increase in cash     1,586       35,668  

 

Operating Activities

 

Net cash used in operating activities of approximately $4,226,000 during the six months ended June 30, 2020 consists primarily of net loss, less adjustments for depreciation and amortization expenses, revaluation of liability in respect of warrants and rights of purchase and share-based payments, as well as a decrease in trade receivables.

 

4

 

 

Net cash used in operating activities of approximately $8,297,000 during the six months ended June 30, 2019 consists primarily of net loss, less adjustments for depreciation and amortization expenses, revaluation of liability in respect of warrants and rights of purchase, issuance expenses and share-based payments, as well as an increase in inventory.

 

The decrease is mainly as a result of a smaller increase in inventory, a decrease in trade receivables, and a decrease in net loss less adjustments to net loss.

 

Investing Activities

 

Net cash used in investing activities of approximately $9,978,000 during the six months ended June 30, 2020 was primarily used for investment in bank deposits.

 

Net cash used in investing activities of approximately $330,000 during the six months ended June 30, 2019 was primarily used for purchases of fixed assets.

 

Financing Activities

 

Net cash provided by financing activities of approximately $49,872,000 in the six months ended June 30, 2020 consisted primarily of net proceeds from the issuance of ordinary shares (including ADSs) and exercise of warrants.

 

Net cash provided by financing activities of approximately $10,213,000 in the six months ended June 30, 2019 consisted primarily from net proceeds from the issuance of ordinary shares (including ADSs), warrants and rights to purchase ADSs.

 

In February 2020, pursuant to a public offering in the United States, we issued an aggregate of 2,333,000 ADSs. Also, in February 2020, the underwriters partly exercised their over-allotment option to purchase an additional 255,318 ADSs, bringing the total gross proceeds from the offering to approximately $3,882,000, before deducting underwriting discounts and commissions and other offering-related expenses. The net proceeds to us were approximately $3,347,000.

 

In April 2020, pursuant to a public offering in the United States, we issued an aggregate of 17,428,000 ADSs and 430,000 pre-funded warrants exercisable into 430,000 ADSs. Also, in April 2020, the underwriters partly exercised their over-allotment option to purchase an additional 1,204,114 ADSs, bringing the total gross proceeds from the offering to approximately $13,343,000, before deducting underwriting discounts and commissions and other offering-related expenses. The net proceeds to us were approximately $11,508,000.

 

In May 2020, pursuant to a public offering in the United States, we issued an aggregate of 17,950,000 ADSs. The total gross proceeds from the offering were approximately $35,900,000, before deducting underwriting discounts and commissions and other offering-related expenses. The net proceeds to us were approximately $30,913,000.

 

Outlook

 

To date, we have not achieved profitability and have sustained net losses in every fiscal year since our inception, and we have financed our operations primarily through proceeds from issuance of our ordinary shares (including ADSs) and other convertible securities.

 

Until we can generate significant recurring revenues and achieve profitability, we will need to seek additional sources of funds through the sale of additional equity securities, debt or other securities. Any required additional capital, whether forecasted or not, may not be available on reasonable terms, or at all. If we are unable to obtain additional financing or are unsuccessful in commercializing our products and securing sufficient funding, we may be required to reduce activities, curtail or even cease operations.

 

In addition, our operating plans may change as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our future capital requirements will depend on many factors, including:

 

  the progress and costs of our research and development activities;
     
  the progress in the launch of the commercial DragonFly LDM system;
     
  the costs of manufacturing our DragonFly LDM system and ink products;
     
  the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;
     
  the potential costs of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally; and
     
  the magnitude of our general and administrative expenses.

 

 

 5